# Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function

> **NCT00478361** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 40 (actual)

## Conditions studied

- Distal Urethral Cancer
- Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter
- Proximal Urethral Cancer
- Recurrent Bladder Cancer
- Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter
- Recurrent Urethral Cancer
- Regional Transitional Cell Cancer of the Renal Pelvis and Ureter
- Stage III Bladder Cancer
- Stage IV Bladder Cancer
- Transitional Cell Carcinoma of the Bladder
- Urethral Cancer Associated With Invasive Bladder Cancer

## Interventions

- **DRUG:** Gemcitabine hydrochloride
- **DRUG:** Paclitaxel
- **DRUG:** Doxorubicin hydrochloride
- **DRUG:** Pegfilgrastim

## Key facts

- **NCT ID:** NCT00478361
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2020-10-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00478361

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00478361, "Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00478361. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*